Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Moderate Buy” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.5714.

A number of research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday. Royal Bank Of Canada reduced their target price on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wall Street Zen downgraded Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Finally, Mizuho lowered their price target on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, June 18th.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $1.65 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09. The company has a fifty day moving average of $1.64 and a two-hundred day moving average of $2.15. The stock has a market capitalization of $305.71 million, a PE ratio of -1.24 and a beta of 2.74. Neumora Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. As a group, research analysts forecast that Neumora Therapeutics will post -0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NMRA. Hsbc Holdings PLC purchased a new stake in shares of Neumora Therapeutics during the fourth quarter worth $27,000. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics in the third quarter worth about $31,000. Fred Alger Management LLC purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth about $40,000. Canada Pension Plan Investment Board acquired a new position in Neumora Therapeutics during the second quarter worth about $41,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Neumora Therapeutics during the third quarter worth about $44,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.